Treatment of Inflammatory Bowel Disease with Biologics
237 inflammatory skin lesions after initiating biologic therapy [ 29 , 30 ]. While the timing of these skin lesions occurring af ...
238 Eczematiform Lesions Eczema-like lesions are characterized by xerosis and pruriginous plaques with ery- thematous or squamou ...
239 receiving anti-TNF therapy for IBD, Rahier et al. found that 42/60 (68%) in the psoriasiform group and 20/23 (87%) in the e ...
240 Psoriasiform and eczematiform lesions appear to be reactions to the class of drugs rather than to the individual anti-TNF ag ...
2 41 vectors in many innate immune responses [ 46 ]. When both cytokines are in balance, the result is an equilibrium allowing p ...
242 Management of anti-TNF psoriasiform lesions generally does not require ces- sation of anti-TNF agent [ 36 ]. For mild diseas ...
243 Lupus-Like Syndrome Clinical Presentation Lupus-like syndrome (LLS), a rare autoimmune disorder, is a recognized adverse rea ...
244 Onset of LLS has been reported to range from 10 days to 54 months after initia- tion of anti-TNF [ 60 ]. In a case series of ...
245 formation (p = 0.05) and LLS development (p = 0.04) [ 52 ]. Others have found that ANA and dsDNA can be detected in CD patie ...
246 Management of anti-TNF therapy-associated LLS involves withdrawal of anti- TNF therapy with or without the addition of stero ...
247 therapy [ 69 ]. When identifying cases of drug-induced liver injury (DILI) caused by anti-TNF agents in Iceland from 2009 to ...
248 The majority of reported cases of hepatotoxicity associated with anti-TNF agents have been in women [ 69 – 71 ]. The mean ag ...
249 from corticosteroid therapy [ 70 ]. Autoantibodies, particularly ANA, tend to decrease or disappear after corticosteroid the ...
250 reported as 3.2 per 100,000 persons per year [ 79 ]. Given its high efficacy in treat- ment of rheumatoid arthritis (RA) and ...
251 well understood what other baseline characteristics predispose patients to develop demyelinating disease after anti-TNF ther ...
252 Diagnosis and Management Although the pathogenic mechanism of anti-TNF-induced demyelinating diseases is not yet clearly del ...
253 eases [ 82 ]. The majority of reported cases have complete or near-complete resolution of neurological symptoms after discon ...
254 [ 92 ]. Nineteen out of 38 patients (50%) who developed new-onset heart failure had no identifiable risk factor for heart fa ...
255 heart during ischemic injury [ 103 ]. Furthermore, TNF-α induces production of nitric oxide which maintains peripheral blood ...
256 Kugathasan S, et al. Infliximab retreatment in adults and children with Crohn’s disease: risk factors for the development ...
«
8
9
10
11
12
13
14
15
16
17
»
Free download pdf